Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies

David Hoon's Biography

David Hoon, Professor, Director Department of Translational Molecular Medicine, John Wayne Cancer Institute

Professor Hoon is a pioneer in “liquid biopsy” translational studies; have received multiple grants and published since the mid 90’s in the fields of circulating tumor cells (CTC) and cell free nucleic acids (CFNA) as prognostic, predictive, and diagnostic molecular biomarkers. I have significant expertise, leadership, and publication record in the field in the last 20 years. Professor Hoon expertise includes multiple patents (USA, International). Some of the liquid biopsy assays have been transferred to biotech companies. Professor Hoon is an advisor, scientific board member, and founder on multiple biotech companies as well as CLIA biotechs in liquid biopsy analysis in the USA and internationally. Professor Hoon has run several phase II/III clinical trials as companion Dx on liquid biopsy showing clinical utility. Professor Hoon is on the executive advisory board and member participant of CANCER-ID European International Program; a Multicenter Clinical Trial group verifying and validating CFNA. Over the last 20 years Professor Hoon has developed new approaches and techniques in isolation of CFNA as well as interrogating many forms in multiple types of solid tumors including melanoma, breast, lung, gastrointestinal, and brain tumors. Through Professor Hoon's position as a PI co-Investigator on multiple CA state, DOD, Biotech, Pharma, and NIH-funded grants(R21, R33, PO1s, RO1s), Professor Hoon has extensive experience and publications. Professor Hoon has served as Chairman several times on the SBIR NIH CFDNA phase I/II grant reviews. Professor Hoon is one of the pioneers in the 90’s demonstrating clinical utility of CFNA in patients relating to clinical outcomes. In addition Professor Hoon has extensive experience in translational molecular oncology relating to diagnostic and prognostic genomic, transcriptome and epigenetic biomarkers in tissues in Phase I/II/III clinical trials.

David Hoon Image

New Approaches of Next Generation Sequencing of Circulating DNA in Cancer Patients

Monday, 27 October 2014 at 15:30

Add to Calendar ▼2014-10-27 15:30:002014-10-27 16:30:00Europe/LondonNew Approaches of Next Generation Sequencing of Circulating DNA in Cancer

Circulating-free DNA (cfDNA) has been shown to be useful blood cancer biomarkers over the last decade. cfDNA can be used to monitor tumor progression, tumor response to treatment, and early detection of tumor recurrence. cfDNA biomarkers can occur in different forms such as mutations, amplification, loss of heterozygosity(LOH), methylation, and size integrity. We have shown the clinical utility of all these blood biomarkers in various solid tumors. Over the past years different assay approaches have been employed to detect cfDNA such as PCR based assays. However the major issue has been developing clinical utility for health payer reimbursement.  More recently the utilization of Next Generation Sequencing (NGS) has taken the assessment of cfDNA to a higher level of accuracy and sensitivity. We have employed a novel digital NGS approach in collaboration with Guardant Health for ultra-sensitive detection of cfDNA in approximately 2 ml of serum of solid tumors. Studies were designed in solid tumors such as melanoma with paired tumor tissues and serum. NGS was performed at 1000x coverage of the entire panel of 60 genes which allowed accurate detection of mutations/deletions across the complete gene as opposed to single targeted regions of a gene. We demonstrated high correlation of cfDNA to respective tumors and association with clinical tumor progression. The assay is now CLIA lab approved.  Currently, we are validating the assay in multi-institute settings.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid